{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.40","upperLimit":"19.40","value":"14.80"},{"groupId":"OG001","lowerLimit":"1.90","upperLimit":"28.80","value":"20.00"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG002","lowerLimit":"4.90","upperLimit":"NA","value":"7.25"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG003","lowerLimit":"2.80","upperLimit":"NA","value":"4.65"},{"groupId":"OG004","lowerLimit":"3.5","upperLimit":"39.6","value":"10.60"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG005","lowerLimit":"5.60","upperLimit":"NA","value":"20.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"description":"Duration of overall response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 1; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG001","title":"Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG002","title":"Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.","id":"OG003","title":"Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG004","title":"Phase 2: Cohort 7; FT-2102 (Single Agent)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG005","title":"Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)"}],"paramType":"MEDIAN","populationDescription":"FAS included all the participants who were enrolled in the study and have received at least one dose of FT-2102. Data is reported only for Cohort 1, 4, 5, 6, 7 and 8. No participants achieved an overall response in Phase 2 Cohort 3. Duration of Response is not calculated for Phase 2 Cohort 2. Here, Overall Number of Participants Analyzed = participants with overall response for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Phase 2: From the date of the first response to the date of the relapse or death (up to 82 months)","title":"Phase 2: Duration of Overall Response for Acute Myeloid Leukemia (AML)","type":"SECONDARY","unitOfMeasure":"Months"}